Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease
Authors
Keywords
LCI699, Osilodrostat, 11β-hydroxylase, Cushing’s, Cortisol
Journal
Pituitary
Volume 19, Issue 2, Pages 138-148
Publisher
Springer Nature
Online
2015-11-05
DOI
10.1007/s11102-015-0692-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Treatment of Cushing's Disease
- (2015) Rosario Pivonello et al. ENDOCRINE REVIEWS
- Cushing's syndrome
- (2015) André Lacroix et al. LANCET
- AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease
- (2014) Amir Hamrahian et al. Endocrine Practice
- Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone
- (2014) Maria Fleseriu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Ketoconazole in Cushing's Disease: Is It Worth a Try?
- (2014) Frederic Castinetti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment of Cushing's disease: a mechanistic update
- (2014) Daniel Cuevas-Ramos et al. JOURNAL OF ENDOCRINOLOGY
- Testosterone and cardiovascular disease
- (2014) C. Mary Schooling Current Opinion in Endocrinology Diabetes and Obesity
- Efficacy of medical treatment in Cushing's disease: a systematic review
- (2013) Mônica R. Gadelha et al. CLINICAL ENDOCRINOLOGY
- Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing's disease: care reality in the Munich Metropolitan Region
- (2013) C Dimopoulou et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Approach to the Cushing's Disease Patient With Persistent/Recurrent Hypercortisolism After Pituitary Surgery
- (2013) Xavier Bertagna et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
- (2013) Philippe J. Caron et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study
- (2013) Xavier Bertagna et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
- (2012) A. J. van der Lely et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome
- (2012) Maria Fleseriu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Medical management of Cushing’s disease: what is the future?
- (2012) Maria Fleseriu et al. Pituitary
- Management of Cushing disease
- (2011) Nicholas A. Tritos et al. Nature Reviews Endocrinology
- Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas during Treatment with Pegvisomant: A Prospective Multicenter Study
- (2009) Jan-Hendrik Buhk et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cushing's Syndrome
- (2008) Rosario Pivonello et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement
- (2008) B. M. K. Biller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search